Akari Therapeutics, Plc (AKTX) Earnings History
Net Loss16 years of earnings data (2010–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Akari Therapeutics, Plc (AKTX) Earnings Overview
As of June 30, 2026, Akari Therapeutics, Plc (AKTX) reported trailing twelve-month net income of -$28M, reflecting +84.3% year-over-year growth. The company earned $-1333.08 per diluted share over the past four quarters.
Looking at the long-term picture, AKTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$675,000 in fiscal 2010.
Akari Therapeutics, Plc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ALXO (-$89M net income), CRVS (-$44M net income), OMAB ($5.29B net income, 33.5% margin), AKTX has comparable earnings metrics. Compare AKTX vs ALXO →
AKTX Earnings vs Peers
Earnings metrics vs comparable public companies
AKTX Historical Earnings Data (2010–2025)
16 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$17M | +12.6% | -$17M | $-20800.00 | - | - |
| 2024 | -$20M | -97.8% | -$22M | $-132800.00 | - | - |
| 2023 | -$10M | +43.6% | -$17M | $-163200.00 | - | - |
| 2022 | -$18M | -1.9% | -$23M | $-455200.00 | - | - |
| 2021 | -$17M | -2.0% | -$17M | $-649600.00 | - | - |
| 2020 | -$17M | -1.4% | -$18M | $-896000.00 | - | - |
| 2019 | -$17M | +15.6% | -$25M | $-999999.00 | - | - |
| 2018 | -$20M | +28.6% | -$20M | $-999999.00 | - | - |
| 2017 | -$28M | -53.9% | -$35M | $-999999.00 | - | - |
| 2016 | -$18M | +60.0% | -$27M | $-999999.00 | - | - |
| 2015 | -$45M | -369.7% | -$31M | $-999999.00 | - | - |
| 2014 | -$10M | -166.5% | -$10M | $-999999.00 | - | - |
| 2013 | -$4M | -152.3% | -$4M | $-999999.00 | - | - |
| 2012 | -$1M | +32.3% | -$4M | $-48.00 | - | - |
| 2011 | -$2M | -213.9% | -$2M | $-64.00 | - | - |
| 2010 | $-675,000 | - | $-792,000 | $-16.00 | - | - |
Download Data
Export AKTX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
16+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AKTX — Frequently Asked Questions
Quick answers to the most common questions about buying AKTX stock.
What is AKTX earnings per share (EPS)?
AKTX trailing twelve-month (TTM) diluted EPS is $-1333.08, reflecting +84.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2010 to 2025 is available in the table on this page.
What is Akari Therapeutics, Plc's net income?
Akari Therapeutics, Plc (AKTX) trailing twelve-month net income is $-28M as of 2025. Earnings grew +84.3% year-over-year.
Is AKTX profitable?
AKTX is not currently profitable on a TTM basis, reporting a net loss of $-28M. Net margin is N/A. Investors should monitor for a return to profitability.
What is AKTX's earnings growth rate?
AKTX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2010 to 2025.
What are AKTX's profit margins?
Akari Therapeutics, Plc net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -68.4%.
Is AKTX growing earnings?
Yes, AKTX earnings are accelerating — EPS growth of +84.3% exceeds the 5-year CAGR of N/A. TTM net income reached $-28M. Earnings momentum is strengthening.
What was AKTX's best earnings year?
Akari Therapeutics, Plc's highest annual net income on record is $-675000.00, achieved in fiscal year 2010. Earnings history on this page spans 2010 to 2025 and includes all annual and quarterly figures.
What were AKTX's earnings last quarter?
AKTX's most recent reported quarter was Q1 2026. Net income was $-14M with diluted EPS of $-688.00. For a full breakdown of all quarters, see the quarterly earnings table on this page.